Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry

Por Wagstaff, J., Jones, R., Hawkins, R., Porfiri, E., Pickering, L., Bahl, A., Brown, J., Buchan, S.
Publicado no Ann Oncol (2016)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer

Por Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.
Publicado em 2011

Medication Burden of Treatment Using Oral Cancer Medications

Por Given, Barbara A., Given, Charles W., Sikorskii, Alla, Vachon, Eric, Banik, Asish
Publicado no Asia Pac J Oncol Nurs (2017)

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy

Por Wheler, J. J., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Piha-Paul, S. A., Chen, S. S., Fu, S., Stephen, B., Fok, J. Y., Janku, F., Kurzrock, R.
Publicado em 2013

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population

Por Buti, S, Puligandla, M, Bersanelli, M, DiPaola, R S, Manola, J, Taguchi, S, Haas, N B
Publicado no Ann Oncol (2017)

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated...

Por Montero, A. J., Diaz-Montero, C. M., Millikan, R. E., Liu, J., Do, K.-A., Hodges, S., Jonasch, E., McIntyre, B. W., Hwu, P., Tannir, N.
Publicado no Ann Oncol (2009)

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies

Por Voss, M. H., Bastos, D. A., Karlo, C. A., Ajeti, A., Hakimi, A. A., Feldman, D. R., Hsieh, J. J., Molina, A. M., Patil, S., Motzer, R. J.
Publicado no Ann Oncol (2014)

Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors

Por Erickson-Miller, Connie L., Chadderton, Antony, Gibbard, Anna, Kirchner, Jennifer, Pillarisetti, Kodandaram, Baker, Katherine, Pandite, Lini, El-Hariry, Iman, Mostafa Kamel, Yasser, Liu, Yuan, Martin, Anne-Marie, Messam, Conrad
Publicado em 2010

Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

Por Keefe, S. M., Hoffman-Censits, J., Cohen, R. B., Mamtani, R., Heitjan, D., Eliasof, S., Nixon, A., Turnbull, B., Garmey, E. G., Gunnarsson, O., Waliki, M., Ciconte, J., Jayaraman, L., Senderowicz, A., Tellez, A. B., Hennessy, M., Piscitelli, A., Vaughn, D., Smith, A., Haas, N. B.
Publicado no Ann Oncol (2016)

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

Por Rugo, H. S., Hortobagyi, G. N., Yao, J., Pavel, M., Ravaud, A., Franz, D., Ringeisen, F., Gallo, J., Rouyrre, N., Anak, O., Motzer, R.
Publicado no Ann Oncol (2016)

Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors

Por Zhao, X., Suryawanshi, S., Hruska, M., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., Bello, A., Roy, A., Agrawal, S.
Publicado no Ann Oncol (2017)